Please assess the completion status of the following clinical trial:

Trial Title: Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 21 - 65 years old at time of screening visit. Both genders and any race will be accepted.~* Diagnosis of BPD I or II without significant co-morbid secondary medical or psychiatric diagnoses; no substance abuse or dependence during preceding 12 months~* A minimum score of 18 on the first 17 items of the 21-item Hamilton Depression Scale~* Willingness to washout for a reasonable time (depending on the substance) from: Vitamin E and fish oils (\>600 IU/day), non-aspirin NSAIDs or aspirin (\>81 mg/day, H2 receptor antagonists, Ginko biloba, caffeine on morning of blood drawing, and to institute lights-out at 23:00 hours on the nights before blood drawings~Exclusion Criteria:~* Any abnormal findings on the physical exam, ECG, blood/urine or minor infections~* Any pre-existing physical pain condition, including fibromyalgia~* History of peptic ulcer complicated by perforation, hemorrhage, or obstruction; symptoms of peptic ulcer within 4 weeks of enrollment date~* Any substance abuse or dependence during the preceding 12 months~* Clinically significant hypertension, anemia, liver disease, kidney disease, arthritis, diabetes, recurrent migraines, epilepsy, stroke, gum disease, autoimmune disease~* Current use of lithium~* Current use of a stimulant~* Certain steroids including use of hormonal birth control and any systemic or topical corticosteroids (hormone replacement therapy will be allowed)~* Unwillingness to refrain from H2 receptor antagonists, non-aspirin NSAIDs, or aspirin (more than 1 mg/day).~* Use of any anticoagulant agents~* Use of nicotine-containing substances. Subjects who quit smoking more than 3 months prior to assessment may be considered for the study~* Known sensitivity or allergy to the study medications or a need to receive agents that are contra-indicated in combination with CBX or ESC~* Unwillingness to fast and abstain from caffeine on mornings of blood drawings~* A sleep disorder other than insomnia or hypersomnia as a distinct symptom of major depressive disorder (MDD)~* Inability to commit to the follow-up visits between 8 and 11 am

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention cohort (Type: EXPERIMENTAL): Participants assigned to the intervention cohort receive 10mg escitalopram twice daily plus 200mg celecoxib twice daily.
- Control cohort (Type: PLACEBO_COMPARATOR): Participants assigned to the control cohort receive 10mg escitalopram twice daily plus placebo administered twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).